Last Updated : Monday, December 2, 2019 11:45:47

SUN PHARMA denied dismissal of certain claims in an ongoing lawsuit in US

VADODARA (BARODA) | MUMBAI | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update submitted to the Indian Stock Exchanges, Vadodara (Baroda) headquartered Indian Pharmaceutical major – Sun Pharmaceutical Industries Ltd said of having updated on the ongoing litigation in regards to Ranbaxy Generic Drug Application Anti-Trust litigation in US Courts, where the US District court has denied dismissal of claims of certain plaintiffs, to the Company.

The company along with its subsidiaries is a defendant in multi-district litigation, brought by various classes of plaintiffs in the US District Court, alleging the delay in the market entry of three generic drugs.

The company update as submitted to the Indian Bourses – with subject title, “In re: Ranbaxy Generic Drug Application Antitrust Litigation in US,” further read that, the Company along with its wholly owned subsidiaries (together “Sun Pharma”) is a defendant in a multi-district litigation brought by various classes of plaintiffs, in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs (Valganciclovir, Valsartan and Esomeprazole).

The complaints assert claims under the Racketeer Influenced and Corrupt Organizations Act, federal and state antitrust laws, and state consumer protection laws.

These litigations have already been disclosed in the Company’s 2018-19 annual report.

On November 27, 2019, the US District Court (District of Massachusetts) entered a decision denying in part and granting in part Sun Pharma’s motion to dismiss the claims of certain plaintiffs.

Under the ruling the majority of those plaintiff’s claims survive and several state law claims are dismissed.

The litigation is proceeding in discovery.

Sun Pharma will continue to vigorously defend against all claims and is also considering its appeal options as to the claims that were not dismissed in the above court decision.

To read more, please CLICK here.


FacebookLinkedinTwitterYouTube, Blogspot, Telegram, Instagram 

You can also access and/or read the above narrated news-report on our : BLOG and/or WEBSITE.


Do NOT follow this link or you will be banned from the site!